Anti-epileptic drugs (AEDs) are the main type of treatment for most people with epilepsy. Up to 70% of people could stop having seizures with the right medication. AED’s are preventative medication taken every day to try and stop seizures from happening. The developed app gives a comparison between healthcare utilization and costs in patients treated with long-acting (LA) vs short-acting (SA) Anti-epileptic drug (AED) monotherapy. The report provides insights on drug effectiveness and utilization to provide concrete findings to accelerate the business of pharma companies. Physicists, R&D Professionals, and Scientists in Pharma and Healthcare Domain are the end-users of this application.

 

Challenges

  • Lack of comprehensive study on AED’s on a single platform
  • There are over 20 AEDs and each has a particular type or types of seizures that it works for, collating data for different AED’s and linking it with other metrics remained a challenge
  • Lack of information about patients concerning demographics, gender, and interlinked comorbidities
  • Lack of systematic bifurcation study on long-acting (LA) vs short-acting (SA) anti-epileptic drug (AED)

 

Solution

Our solution enabled the following capabilities to address customer challenges :

  • Interactive and seamless interface that accelerated the decision-making process
  • Powerful Insights suggestive of a comprehensive study on AED’s
  • Insights into each AED with healthcare costs and healthcare utilization
  • Advanced analytics comparing long-acting (LA) vs short-acting (SA) AED’s with respect to demographics, Physician speciality, Healthcare costs,etc.
  • Key insights into patients receiving AED’s with extended duration have lower healthcare costs and improved health and economic outcome
33.4%

Reduced time to Insight

52.5%

Reduced maintenance and cost ffforts

+41.7%

Increase in informed decision making by patients

+67%

Increase in sales margin of AED manufacturers